When given alongside endocrine therapy (ET), Verzenio (abemaciclib) can lower the risk of cancer recurrence and spread compared to standard ET alone in patients with certain forms of early breast cancer who have a high risk of seeing their disease return and spread elsewhere, according to results from a Phase 3 trial. Data from the study’s interim analysis were presented at the recent European Society for Medical Oncology 2020 Virtual Congress and simultaneously published in the…
You must be logged in to read/download the full post.
The post Verzenio With Endocrine Therapy Can Lower Risk of Recurrence, Spread in Early Breast Cancer, Trial Shows appeared first on BioNewsFeeds.